Genetic Heterogeneity of Beta Thalassemia Mutations in Kahramanmaraş Province in Southern Turkey: Preliminary Report

Ergul Belge Kurutas¹, Mehmet Emrah Aksan¹, Petek Curuk², Mehmet Akif Curuk³

¹ Department of Medical Biochemistry, Faculty of Medicine, Sutcu Imam University, Kahramanmaraş, Turkey
² Department of Microbiology, Health Sciences Institute, Çukurova University, Adana, Turkey
³ Department of Medical Biochemistry, Faculty of Medicine, Çukurova University, Adana, Turkey

Corresponding author: Ergul Belge Kurutas, Department of Medical Biochemistry, Faculty of Medicine, Sutcu Imam University, 46050, Avsar Campus, Kahramanmaraş, Turkey; E-mail: ergulkurutas@gmail.com; Tel.: +90 3442803336

Received: 19 June 2020  •  Accepted: 21 Oct 2020  •  Published: 31 Oct 2021

Citation: Kurutas EB, Aksan ME, Curuk P, Curuk MA. Genetic heterogeneity of beta thalassemia mutations in Kahramanmaraş province in Southern Turkey: preliminary report. Folia Med (Plovdiv) 2021;63(5):697-703. doi: 10.3897/folmed.63.e55627.

Abstract

Introduction: Beta thalassemia is one of the most common autosomal single-gene disorders in the world. The prevalence of the disease is in the “thalassemia belt” which includes the Mediterranean region of Turkey. Throughout the country, the gene frequency is estimated to be 2.1%, but in certain regions, it increases up to 10%.

Aim: In this first study, we aimed to determine the frequency of β-thalassemia trait and distribution of mutations in Kahramanmaraş province located in the southern part of Turkey.

Materials and methods: In this study, 5-ml blood samples were taken from 14 thalassemic patients and their relatives who were taking care of them in Sutcu Imam University Hospital at Kahramanmaraş. Also, we collected blood samples from 245 adults for screening beta thalassemia trait. Haematological data were obtained by cell counter. HbA₂ was determined by HPLC. Ten common mutations were screened by the amplification refractory mutation system (ARMS) method. These β-thalassemia mutations are: -30 (T>A), Fsc8 (-AA), Fsc8/9 (+G), IVS1-1 (G>A), IVS1-5 (G>C), IVS1-6 (T>C), IVS1-110 (G>A), Cd 39 (C>T), IVS2-1 (G>A), IVS 2-745 (C>G). A rare mutation, Fsc44 (-C) was characterized by DNA sequencing.

Results: Ten patients were identified as homozygous for IVS1-110 (seven cases), Fsc44 (two cases) and IVS1-5 (only one case). The rest of the 4 patients were double heterozygous (two: IVS1-110/IVS1-6, one: Fsc8/Fsc8-9, one: IVS2-1/IVS1-5). In 245 adult, five β-thalassemia trait carriers were detected by screening survey.

Conclusions: Sixteen alleles were detected as IVS1-110 in 57.1%. It was seen as the most common mutation in Kahramanmaraş. Seven different β-thalassemia mutations were found in this study. Each of 10 families had only one thalassemic patient, other two families had double thalassemic patient, 12 families in total. Furthermore, we found that the incidence of β-thalassemia trait was 2.04% in the province of Kahramanmaraş in southern Turkey.

Keywords

β-thalassemia mutations, Fsc44 (-C), Kahramanmaraş
INTRODUCTION

β-thalassemia is an autosomal recessive disorder characterized by microcytosis and hemolytic anemia, which is a result of the reduced synthesis of the β-globin chains of hemoglobin. β-thalassemia major is the most clinically significant of the thalassemias and requires lifelong transfusion therapy that will result in iron overload and subsequent clinical problems unless iron chelation therapy is undertaken. β-thalassemia is much more common in the Mediterranean, West Africa, and large parts of Asia. Turkey is a big country located both on the European and Asian continents. Due to the presence of various ancient civilizations, there is great genetic diversity. Therefore, 20% of the β-thalassemia mutations (42 of 200) and 5% of abnormal hemoglobins (52 of 1000) reported worldwide have been detected in Turkey. Incidence of β-thalassemia trait is given as 2%, but at some regions this ratio increase as high as 10%. IVS1-110 is the most common beta thalassemia mutation in Turkey, and IVS1-6, Fsc 8, IVS1-1, IVSII-745, IVSII-1, Cd39, -30 and Fsc5 mutations follow this. Therefore, it is important to make a screening strategy to clearly establish the prevalence of the β-thalassemia trait in a region and to develop a hemoglobinopathy control program that includes genetic counseling.

Beta thalassemia is a common disease in the Mediterranean region in Turkey. The provinces of Hatay, Adana, Mersin, and Kahramanmaras are in the east Mediterranean region of Turkey. The center of Kahramanmaras and its eleven districts have a population of 1,112,634 as of 2019. Although there were several population screenings for beta thalassemia trait there is no information on β-thalassemia mutations in Kahramanmaras province.

AIM

This is the first study in which we aimed to investigate the genetic heterogeneity of β-thalassemia mutations in the province of Kahramanmaraş in the southern part of Turkey.

MATERIALS AND METHODS

The present study was undertaken with the objective to determine the frequencies of β-thalassemia mutations and their distribution in Kahramanmaras province of Turkey. This study was approved by the Ethics Committee of Sutcu Imam University. We scanned 245 people randomly in Sutcu Imam University Hospital at Kahramanmaras. Haematological data were obtained by a cell counter. HbA2 level was determined by HPLC. Genomic DNA was isolated from leukocytes by DNA extraction kit (Bioneer AccuPrep Genomic Kit). Ten different mutations were screened by ARMS method. These common β-thalassemia mutations are: -30 (T>A), Cd 8 (-AA), Cd 8/9 (+G), IVS 1-1 (G>A), IVS 1-5 (G>C), IVS 1-6 (T>G), IVS 1-110 (G>A), Cd 39 (C>T), IVS 2-1 (G>A), IVS 2-745 (C>G). The primer sequences of mutations are listed in Table 1. After DNA extraction, PCR was set up in two separate tubes for each sample - one test tube for the amplification of the normal ARMS primer and another one for the amplification of the mutant ARMS primer. 20 µL of final PCR reaction volume was used for this purpose. The reaction volume was composed of 0.5 µg of the DNA template, 0.01 µg of each of the four primers (2 control primers: 5’-CAA TGT ATG CCT ATG CCT TTT GCC ACC ACC-3’ and 5’-GAG TCA AGG CTG AGA GAT GCA GGA-3’, one common primer 5’-ACC TCA CCC TGT GGA GCC AC-3’ or 5’-CCC CTT CCT ATG ACA TGA ACT TAA-3’, and 1 mutant/normal ARMS primer for the normal/mutant allele), 0.5 unit Taq DNA polymerase, and 0.2 mM of each dNTP in a solution of 10 mM Tris-HCl, 50 mM MgCl2, and 1 mM spermidine. The PCR cycling was set for 5 minutes initial denaturation at 94°C, followed by 25 cycles at 94°C for 30 seconds, 1 minute at 65°C, and 72°C for 1 minute 30 seconds, and the final extension at 72°C for 10 minutes. Fifteen microliters of the PCR products were mixed with 3 µL of a loading buffer and then loaded on a 2% agarose gel. The gel was set at 100 volts for 1 hour and then stained with ethidium bromide. After staining, the bands could be seen under UV light. A rare β-thalassemia mutation (Fsc44) was characterized by DNA sequencing. The PCR process with the forward primers 5’-CTTAGAGGTTCATTGAATCACGGCTGT-3’ and reverse primer 5’-TATGACAATTTCGGATCGCCTCCCCTTCCTATGACATGA-3’, one denaturing cycle at 96°C for 5 minutes followed by 35 cycles including denaturation at 94°C for 30 seconds, annealing at 62°C for 40 seconds and extension at 72°C for 20 seconds, final extension was at 72°C for 10 minutes. The PCR products were then run on a 2% agarose gel containing ethidium bromide, and visualized under UV light. The polymerase chain reaction products were purified using the QIAquick PCR Purification kit (Qiagen GmbH). The sequencing was performed using forward primer with BigDye Terminator v3.1 Loop Sequencing kit and an ABI PRISMVR 3130 Genetic Analyzer (Applied Biosystems).

RESULTS

Five of 245 samples in Kahramanmaras province were identified as having the β-thalassemia trait. MCV in the most detected β-thalassemia carriers was less than 70 fl and their A2 level was more than 3.7%. Other blood cell indices such as Hb, MCH, and MCHC were lower than normal range in these people. These indices can be found in normal β-thalassemia carriers. The results of β-thalassemia traits are shown in Table 2.

Besides, we investigated β-thalassemia mutation in 14 thalassemic patients and their relatives. While 10 families
had only one thalassemic patient, two families had dou-
able thalassemic patient, 12 families in total. Our results
showed that ten patients were identified as homozygous;
seven IVS1-110 (G>A), two Fsc 44 (-C) and one IVS1-5
(G>C). The rest of the 4 patients were characterized as dou-
able heterozygotes. Two of the cases were IVS1-110/IVS1-6,
another was Fsc8/Fsc8-9 and still another was IVS2-1/
IVS1-5. The list of patient results is presented in Table 3.

Furthermore, 16 chromosomes were detected as IVS1-110
in 14 patients (57.14%). IVS 1-110 (G>A) was seen as the
most common mutation in Kahramanmaraş. Seven dif-
ferent β-thalassemia mutations were found in this study.
The distribution of β-thalassemia mutations detected in
the present study is presented in Table 4.

Table 1. The Amplification Refractory Mutation System (ARMS-PCR) primers

| Mutations       | Primer sequences, 5’→ 3’                                                                 |
|-----------------|--------------------------------------------------------------------------------------------|
| IVS1-110 (G>A) 40M | CTG ATA GGC ACT GAC TCT CTC TGC CTG TTA                                                  |
| IVS1-110 (G>A) 41N | ACC AGC AGC CTA AGG GTG GGA AAA TAC ACC                                                   |
| IVS1-1 (G>A) 42M  | TTA AAC CTG TCT TGT AAC CTT GAT ACG AAT                                                   |
| IVS1-1 (G>A) 43N  | TTA AAC CTG TCT TGT AAC CTT GAT ACG AAC                                                   |
| CD 39 (C>T) 47M   | CAG ATC CCC AAA GGA CTC AAA GAA CCT GTA                                                    |
| CD 39 (C>T) 52N   | TTA GGC TGC TGG TGG TCT ACC CTT GGT CCC                                                    |
| IVS1-6 (C>T)      | TCT CTT TAA ACC TGT CTT GTA ACC TTC ATG                                                    |
| IVS1-6 (C>T)      | TCT CTT TAA ACC TGT CTT GTA ACC TTC ATG                                                    |
| FSC8 (-AA) 54M    | ACA CCA TGG TGC ACC TGA CTC CTG AGC AGG                                                   |
| FSC8 (-AA) 70N    | ACA CCA TGG TGC ACC TGA CTC CTG AGC AGA                                                   |
| -30 (T>A) 57M     | GCA GGG AGG GCA GGA GCC AGG GCT GGG CAA                                                   |
| -30 (T>A) 58N     | GCA GGG AGG GCA GGA GCC AGG GCT GGG CAT                                                    |
| IVS2-1 (G>A) 49M  | AAG AAA ACA TCA AGG GTC CCA TAG ACT GAT                                                    |
| IVS2-1 (G>A) 77N  | AAG AAA ACA TCA AGG GTC CCA TAG ACT GAC                                                    |
| IVS2-74S (C>G) 50M | TCA TAT TGC TAA TAG CAG CTA CAA TCG AGG                                                   |
| IVS2-74S (C>G) 56N | TCA TAT TGC TAA TAG CAG CTA CAA TCG AGC                                                    |
| IVS1-5 (G>C) 88M  | CTC CTT AAA CCT GTC TTG TAA CCT TGT TAG                                                    |
| IVS1-5 (G>C) 89N  | CTC CTT AAA CCT GTC TTG TAA CCT TGT TAC                                                    |
| FSC8/9 (+G) 90M   | CCT TGC CCC ACA GGG CAG TAA CGG CAC ACC                                                   |
| FSC8/9 (+G) 91N   | CCT TGC CCC ACA GGG CAG TAA CGG CAC ACT                                                    |

M: mutant; N: normal

Table 2. Haematological data of five β-thalassemia trait samples from population screening

| Sex-Age | Rbc (1012/L) | Hb (g/dl) | Hct (%) | MCV (fl) | MCH (pg) | MCHC (g/dl) | HbA2 (%) | Hb F (%) | Hb Type | Mutations |
|---------|--------------|-----------|---------|----------|----------|-------------|----------|---------|---------|-----------|
| F-33    | 5.4          | 10.6      | 29.2    | 53.9     | 19.5     | 36.2        | 3.8      | 0.2     | AA      | IVS1-110  |
| F-31    | 5.3          | 11.9      | 35.6    | 67.6     | 22.6     | 33.4        | 4.7      | 0.8     | AA      | IVS1-6   |
| M-35    | 5.8          | 12.5      | 39.3    | 68.0     | 22.0     | 31.9        | 5.0      | 1.6     | AA      | IVS1-110  |
| F-30    | 5.2          | 9.9       | 30.6    | 58.0     | 19.0     | 32.4        | 3.8      | 0.5     | AA      | IVS1-110  |
| F-33    | 5.3          | 10.1      | 33.3    | 62.0     | 19.0     | 30.4        | 3.9      | 0.7     | AA      | Fsc44    |

F: female; M: male

DISCUSSION

Thalassemias, especially β-thalassemia, are a common
genetic disorder in our country. Although the average rate
of β-thalassemia trait is 2.1% in overall Turkey, this rate is
up to 10% in the Mediterranean region and its surrounding
areas. The treatment to sustain life in thalassemia major
is necessary regular blood transfusion with iron chelation
but this requires much commitment on part of the family. The
treatment is also hampered by less of blood resources
available and lack of motivated voluntary donors. The only
cure for affected children is bone marrow transplantation
whose management involves major financial inputs, there-
Table 3. Combination of β-thalassemia mutations for thalassemic patients

| Case number | One of the alleles | The other allele |
|-------------|--------------------|-----------------|
| 1           | Fsc 44             | Fsc 44          |
| 2           | IVS 1-110          | IVS 1-110       |
| 3           | Fsc 8              | Fsc 8/9         |
| 4           | IVS 1-110          | IVS1-6          |
| 5           | IVS 1-110          | IVS1-6          |
| 6           | IVS 1-110          | IVS 1-110       |
| 7           | IVS 1-110          | IVS 1-110       |
| 8           | IVS II-1           | IVS1-5          |
| 9           | IVS 1-110          | IVS 1-110       |
| 10          | IVS1-5             | IVS1-5          |
| 11          | IVS 1-110          | IVS 1-110       |
| 12          | Fsc 44             | Fsc 44          |
| 13          | IVS 1-110          | IVS 1-110       |
| 14          | IVS 1-110          | IVS 1-110       |

The standard definition of the Arab world includes the 22 states and territories from the Atlantic Ocean in the west to the Arabian Sea in the east, and from the Mediterranean Sea in the north to the Horn of Africa and the Indian Ocean in the southeast. It has a combined population of around 350 million people, one-third of whom are under 15 years of age. β-thalassemia is encountered in polymorphic frequencies in almost all Arab countries with carrier rates ranging from 1% to 11%. Among Arabs, the heterogeneity of these mutations varies from 44 different mutations in UAE to 10 in Eastern Saudi Arabia. The most widespread and common mutation among Arabs is IVS-1-110 (G>A). The latter mutation has its highest prevalence in Cyprus and Greece suggesting that it may be of Greek origin. In the Eastern Arabian Peninsula, the Asian Indian mutations (IVS-1-5 (G>C), codons 8/9 (+G) and IVS-1 (~25 bp del) are more common. Furthermore, El-Hashemite et al. reported that of 1.5 million annual live births, approximately 1000 babies are born with β-thalassemia major. The most common mutations in Egyptian children with β-thalassemia are IVS-1-110 (G>A) - 48%, IVS-1-6 (T>C) - 40%, IVS-1-1 (G>A) - 24%, IVS-1-5 (G>C) - 10%, IVS-2-848 (C>A) - 9%, IVS-2-745 (G>C) - 8%, and IVS-2-1 (G>A) - 7%. In the eastern Mediterranean region, Iran is one of the major centres for the prevalence of β-thalassemia. Due to the high consanguinity in the population, it is estimated that there are more than three million β-thalassemia carriers (4%-8%) and 20000 patients. In Jordan, published statistics indicate that there are 1500 major cases and about 150 000 to 200 000 carriers of the disease. Studies have shown that between 5% and 6% of the Lebanese people are carriers of thalassemia minor. The number of affected people in Kuwait is 250-300 patients. High prevalence of β-thalassemia trait in Iraq has been reported. The Emirates, Palestine and Bahrain studies are compatible with the pooled prevalence. The highest prevalence value of this study was reported by Pakistan. As a general conclusion, Pakistan and Iraq have a higher prevalence of β-thalassemia trait values according to their premarital screening results.

In Turkey, the distribution of β-thalassemia alleles displays a decreasing gradient of mutational heterogeneity from East to West Anatolia. Some authors report that 16 different cities in the Marmara, Aegean, and the Mediterranean region between 1995 and 2000, 380 000 healthy subjects were screened. The 16 endemic cities are Adana, Antakya, Antalya, Aydin, Bursa, Denizli, Diyarbakir, Edirne, Isparta, Istanbul, Izmir, Kahramanmaras, Kirkkareli, Mersin, Mugla, and Urfa. Average prevalence of β-thalassemia trait was 4.3%. The highest prevalence of β-thalassemia was reported in the West Mediterranean and in the East Mediterranean, with a frequency of 13.1%.

Table 4. Distribution of beta-thalassemia mutations in Kahramanmaras

| β globin gene mutations | Chromosome number | %    |
|------------------------|-------------------|------|
| IVS 1-110 (G>A)        | 16                | 57.14|
| IVS II-1 (G>A)         | 1                 | 3.57 |
| Fsc 44 (-C)            | 4                 | 14.28|
| Fsc 8 (-AA)            | 1                 | 3.57 |
| IVS 1-5 (G>C)          | 3                 | 10.71|
| IVS 1-6 (T>C)          | 2                 | 7.14 |
| Fsc 8/9 (+G)           | 1                 | 3.57 |
| Total                  | 28                | 100  |
We conducted the first molecular study in Kahramanmaraş province which is in the East Mediterranean region of Turkey. In our study, we scanned randomly 245 people (5 of 245 samples were identified as having the β-thalassemia trait), and found the incidence of β-thalassemia trait to be 2.04% in Kahramanmaraş. Also, in our study, 7 different mutations were detected, the most frequent being IVS1-110 (G>A) - 57.14%. Other mutations that were encountered include Fsc 44 (-C), IVS1-5 (G>C), IVS2-1 (G>A), IVS1-6 (C>T), Fsc 8 (-AA), and Fsc 8/9 (+G). These 6 mutations made up 42.86% of all detected mutations. In our study, IVS1-110 (G>A) mutation was identified in 57.14% which appears to be related to consanguineous marriages in Kahramanmaraş province. Also, there is one heterozygous person carrying this mutation in our screening study. This mutation is very common in Kahramanmaraş. In addition, the first screening studies in Kahramanmaraş were initiated by Yuregir et al. in 2001.31 They scanned 1491 persons at random, and the incidence of β-thalassemia trait was found to be 0.93% in Kahramanmaraş. The other group made premartial screening of 1109 people in Kahramanmaraş -Elbistan in 2003 and they found the incidence of β-thalassemia to be 0.90%.30 Kahramanmaraş Health Authorities organized premartial screening center, 48126 people were scanned between January 2006 and January 2009, the prevalence of β-thalassemia and sickle cell anemia was 2.8% and 0.4%, respectively.31 After these comprehensive studies, premartial screening tests were made compulsory for all couples to marry by the government in Kahramanmaraş. Some research reported the results of prenatal diagnosis of sickle cell and β-thalassemia in Adana.32,33 They found that 57.3% of the IVS1-110 mutation incidence was due to parents carrying β-thalassemia specificity. Fsc 44 was reported by Rund et al. to be a frequent mutation (31.2%) in the Jews of Kurdish in North Iraq.34 Our study showed the second frequency for Fsc44 (14.28%) in Kahramanmaraş province. These results confirm that β-thalassemia mutations are highly heterogeneous, attributed to the ethnic characteristics in different parts of Turkey. This is the first study to determine the frequencies of β-thalassemia mutations in the city of Kahramanmaraş. When a patient is born with β-thalassemia, there is no effective treatment option except bone marrow transplantation. Therefore, the best method for dealing with β-thalassemia is prenatal diagnosis. In the current study, six families who carry the β-globin gene mutation were given genetic consultation for prenatal diagnosis based on DNA analysis.

CONCLUSIONS

After we have identified the mutations in β-thalassemia patients living in the city of Kahramanmaraş, the number of cases of prenatal diagnosis will promptly increase. Therefore, this will provide important benefits to the population health and the national economy as well.

Acknowledgements

We express our gratitude to all staff of pediatrics unit at Kahramanmaraş Sutcu Imam University for collecting blood samples for this study.

Financial support and sponsorship

This study was supported financially by the Kahramanmaraş Sutcu Imam University Scientific Research Project unit (Project numbers: 2015/1-31 YLS and 2015/1-32 YLS). This unit had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Howard J, Davies SC. Haemoglobinopathies. Paediatr Child Health 2007; 17:311–6.
2. Tadmouri GO, Tuzmen S, Ozcelik H, et al. Molecular and population genetic analyses of beta-thalassemia in Turkey. Am J Hematol 1998; 57:215–20.
3. CURUK MA, Yalin E, Aksoy K. Prevention of hemoglobinopathies in Turkey. Thalassemia Reports 2013; 3:e1.
4. CURUK MA, Arpaci A, Attila G, et al. Genetic heterogeneity of β-thalassemia at Çukurova in Southern Turkey. Hemoglobin 2001; 25:241–5.
5. Akar E, Akar N. A review of abnormal hemoglobins in Turkey. Turkish J Hematol 2007; 24:143–5.
6. De Sanctis V, Kattamis C, Canatan D, et al. β-thalassemia distribution in the old world: An ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis 2017; 59:e2017018.
7. Newton CR, Graham A, Hepatinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acid Res. 1989; 17:2503–16.
8. Chaudhary S, Dhawan D, Sojitra N, et al. Whole gene sequencing based screening approach to detect β-thalassemia mutations. Biol Med (Aigargh) 2017; 9:383.
9. Mishra AK, Tiwari A. Iron overload in beta thalassaemia major and intermedia patients. Maedica (Buchar) 2013; 8:328–32.
10. Nezhad FH, Nezhad KH, Choghhakabodi PM, et al. Prevalence and genetic analysis of α- and β-thalassemia and sickle cell anemia in southwest Iran. J Epidemiol Glob Health 2018; 8:189–95.
11. Kountouris P, Kouziappa I, Papasavva T, et al. The molecular spectrum and distribution of haemoglobinopathies in Cyprus: a 20-year retrospective study. Sci Rep 2016; 6:26371.
12. Baysal E, Indrak K, Bozkurt G, et al. The beta thalassaemia mutations in the population of Cyprus. Br J Haematol 1992; 81:607–9.
13. Malamos B, Fessas P, Stamatoyannopoulos G. Types of thalassemia trait carriers, as revealed by a study of their incidence in Greece. Br J
14. Kattamis C, Hu H, Cheng G, et al. Molecular characterization of β-thalassemia in 174 Greek patients with thalassemia major. Br J Haematol 1990; 74:342–46.

15. Hamamy HA, Al-Allawi NA. Epidemiological profile of common haemoglobinopathies in Arab countries. J Community Genet 2013; 4:147–67.

16. El-Hashemite N, Petrou M, Khalifa AS, et al. Identification of novel Asian Indian and Japanese mutations causing β-thalassemia in Egyptian population. Hum Genet 1997; 99:271–4.

17. Hammoud H, Ghanem R, Abdalla R, et al. Genetic mutations of beta thalassemia in middle east countries. WJPPS 2020; 9:134–50.

18. Al-Allawi NA, Al-Dousky AA. Frequency of haemoglobinopathies at premarital health screening in Dohuk, Iraq: implications for a regional prevention programme. East Mediterr Health J 2010; 16:381–5.

19. Hassan MK, Taha JY, Al Naama LM, et al. Frequency of haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Basra. East Mediterr Health J 2003; 9:45–54.

20. Al-Allawi NA, Jalal SD, Ahmed NH, et al. The first five years of a preventive programme for haemoglobinopathies in Northeastern Iraq. J Med Screen 2013; 20:171–6.

21. Al-Allawi NA, Faraj AH, Ahmed NH. Prevalence of haemoglobinopathies in Sulaimani-Iraq. Duhok Med J 2008; 2:71–9.

22. Belhoul KM, Abdulrahman M, Alraei RF. Hemoglobinopathy carrier prevalence in the United Arab Emirates: first analysis of the Dubai Health Authority premarital screening program results. Hemoglobin 2013; 37:359–68.

23. Salama RAA, Saleh AK. Effectiveness of premarital screening program for thalassemia and sickle cell disorders in Ras Al Khaimah, United Arab Emirates. J Genet Med 2016; 13:26–30.

24. Tarazi I, Al Najjar E, Lulu N, et al. Obligatory premarital tests for β-thalassaemia in the Gaza Strip: evaluation and recommendations. Int J Lab Hematol 2007; 29:111–8.

25. Almutawa FJ, Cabrfn JRA. Outcome of premarital counseling of hemoglobinopathy carrier couples attending premarital services in Bahrain. J Bahrain Med Soc 2009; 21:217–20.

26. Shariq M, Moiz R, Zaidi N, et al. Pre-marital screening for beta thalassaemia in Pakistan: an insight. J Med Screen 2014; 21:163–4.

27. Iqbal M, Khan OA, Waseem AG, et al. Carrier frequency of beta thalassemia in twin cities of Islamabad and Rawalpindi. J Rawal Med Coll 2012; 16:73–4.

28. Tozun M, Turhan E, Babaoglu AB. Beta thalassemia trait in Turkey and the Middle East: a meta-analysis of prevalence. Acta Medica Mediterranea 2018; 34:1731.

29. Yüregir GT, Kiliç M, Ekerbiçer H, et al. Screening of hemoglobinopathies in Kahramanmaras, Turkey. Turk J Haematol 2001; 5(18):79–83.

30. Canatan D, Karadogan C, Oguz N, et al. Frequency of consanguineous marriages in patients with hereditary blood disorders in southern Turkey. Community Genet 2003; 6:58.

31. Guler E, Garipardic M, Dalkiran T, et al. Premarital screening test results for β-thalassemia and sickle cell anemia trait in east Mediterranean region of Turkey. Pediatr Hematol Oncol 2010; 27:608–13.

32. Cürük MA, Zeren F, Genç A, et al. Prenatal diagnosis of sickle cell anemia and beta-thalassemia in southern Turkey. Hemoglobin 2008; 32:525–30.

33. Yüzbasioglu Ariyurek S, Yildiz SM, Yalin AE, et al. Hemoglobinopathies in the Çukurova Region and Neighboring Provinces. Hemoglobin 2016; 40:168–72.

34. Rund D, Cohen T, Filon D, et al. Evolution of a genetic disease in an ethnic isolate: Evolution of a genetic disease in an ethnic isolate: beta-thalassemia in the Jews of Kurdistan. Proc Natl Acad Sci USA 1991; 88:310–4.
Генетическая гетерогенность мутаций бета-талассемии в провинции Кахраманмараш в южной Турции: предварительный отчёт

Ергюл Белге Куруташ1, Мехмет Ёмра Аксан1, Петек Джурук2, Мехмет Акиф Джурук3

1 Кафедра медицинской биохимии, Медицинский факультет, Университет „Сутчу Имам“, Кахраманмараш, Турция
2 Кафедра микробиологии, Институт медицинских наук, Университет Луксора, Адана, Турция
3 Кафедра медицинской биохимии, Медицинский факультет, Университет „Сутчу Имам“, Адана, Турция

Адрес для корреспонденции: Ергюл Белге Куруташ, Кафедра медицинской биохимии, Медицинский факультет, Университет „Сутчу Имам“, 46050, Кампус „Авсар“ Кахраманмараш, Турция; E-mail: ergulkurutas@gmail.com; Тел.: +90 3442803336

Дата получения: 19 июня 2020 ♦ Дата приемки: 21 октября 2020 ♦ Дата публикации: 31 октября 2021

Образец цитирования: Kurutas EB, Aksan ME, Curuk P, Curuk MA. Genetic heterogeneity of beta thalassemia mutations in Kahramanmaras province in Southern Turkey: preliminary report. Folia Med (Plovdiv) 2021;63(5):697-703. doi: 10.3897/folmed.63.e55627.

Резюме

Введение: Бета-талассемия – одно из наиболее распространённых аутосомных моногенных заболеваний в мире. Заболевание преобладает в т.н. «Поясе талассемии», который включает Средиземноморский регион Турции. По стране генетическая частота составляет 2.1%, но в некоторых регионах она увеличивается до 10%.

Цель: В этом исследовании нашей целью было определить заболеваемость β-талассемией и распространённость мутаций в провинции Кахраманмараш, расположенной на юге Турции.

Материалы и методы: Для исследования было взято 5 мл крови от 14 пациентов с талассемией и их родственников, которые заботились о них в университетской больнице Сутчу Имам, Кахраманмараш. Мы также взяли образцы крови у 245 взрослых для скрининга на бета-талассемию. Гематологические данные получали путём подсчёта клеток. HbA₂ измеряли с помощью высокоэффективных жидкостных хроматографических колонок (ВЭЖХ). Десять распространённых мутаций были проверены системой amplification refractory mutation system (ARMS). Эти мутации β-талассемии: 30 (T>A), Fsc8 (-AA), Fsc8/9 (+ G), IVS1-1 (G>A), IVS1-5 (G>C), IVS1-6 (T>C), IVS1-110 (G>A), Cd 39 (C>T), IVS2-1 (G>A), IVS 2-745 (C>G). Редкая мутация Fsc44 (-C) была определена путем секвенирования ДНК.

Результаты: Десять пациентов были идентифицированы как гомозиготные по IVS1-110 (семь случаев), Fsc44 (два случая) и IVS1-5 (только один случай). Остальные 4 пациента были дважды гетерозиготными. (два: IVS1-110/IVS1-6, один: Fsc8/Fsc8-9, один: IVS2-1/IVS1-5). Путём скрининга у 2456 взрослых было выявлено пять носителей характерной черты β-талассемии.

Заключение: Для IVS1-110 обнаружено шестнадцать аллелей у 57.1%. Это считается самой распространённой мутацией в Кахраманмараше. В этом исследовании было идентифицировано семь различных мутаций β-талассемии. В каждой из 10 семей был только один пациент с талассемией, в двух других семьях был пациент с двойной мутацией талассемии, всего 12 семей. Кроме того, мы обнаружили, что заболеваемость β-талассемией составила 2.04% в провинции Кахраманмараш, расположенной на юге Турции.

Ключевые слова

мутации β-талассемии, Fsc44 (-C), Кахраманмараш